Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy

Figure 3 Axial computed tomography images in the portal-venous phase of a 65 y/o female, with non-small lung cell carcinoma and a programmed death-ligand 1 expression > 90%, during first-line treatment with Pembrolizumab. A: In the baseline examination, computed tomography (CT) shows a metastatic lesion in the right adrenal gland; B: After 4 wk of treatment, the lesion becomes bigger, with a total increment of 21%, referred to as unconfirmed progression; C-E: during following CT scans, the target lesion shows a progressive dimensional reduction with a total decrease of 46%. These variations in the size of the lesion, during immunotherapy, was in line with pseudoprogression.